Genscript Biotech Corporation (01548.HK) Latest Company News

Oct 22, 2026, 01:47 UTC
Genscript Biotech Corp. rose 1.166% to HK$34.70.
Source:
- aastocks.com
Oct 16, 2026, 01:52 UTC
Hong Kong stocks rose more than 300 points in early trading to 24,392.3, while the Hang Seng Tech Index gained as much as 2.24% to 4,152, with Alibaba and biotechnology shares among the gainers.
Source:
Oct 14, 2026, 09:58 UTC
Southbound funds recorded net sales of HK$135 million in Hong Kong stocks, with net purchases of Alibaba, Akeso, Inc., Meituan and Tencent and net sales of SMIC, Yangtze Optical Fibre and Cable, Xiaomi Corp., Kingboard Laminates Holdings Ltd. and GenScript.
Source:
- aastocks.com
Oct 13, 2026, 12:33 UTC
Legend Biotech Corp announced that CARVYKTI had net trade sales of approximately $710 million for the quarter ended September 30, 2026, based on information provided by JOHNSON & JOHNSON and not independently verified by Legend Biotech Corp or GenScript.
Source:
- finance.sina.cn
- aastocks.com
Oct 13, 2026, 08:12 UTC
Hong Kong-listed shares showed mixed moves, with China Hongqiao falling 5.3% and several stocks including CK Infrastructure, Agricultural Bank of China, Bank of Communications, China Construction Bank and Bank of China reaching record highs.
Source:
- aastocks.com
Oct 13, 2026, 04:12 UTC
Hong Kong-listed shares of Man Wah Holdings Ltd. fell 13.8% to HK$2.37, Genscript Biotech Corp. fell 12.4% to HK$36.90, China Youran Dairy Group Ltd. fell 11.1% to HK$3.43, Mabpharm Ltd. fell 10.8% to HK$19.54, and Brainaurora Medical Technology Ltd. fell 10.1% to HK$0.76.
Source:
- aastocks.com
Oct 9, 2026, 09:50 UTC
AIA Group Ltd. recorded net purchases of HK$291 million in Hong Kong-listed shares, including HK$1.066 billion of AIA, and net sales of several other securities.
Source:
- aastocks.com
Oct 8, 2026, 14:00 UTC
Genscript Biotech Corp. and NVIDIA CORP jointly launched a pitch competition for life-sciences startups to accelerate biotechnology innovation.
Source:
Oct 8, 2026, 09:51 UTC
Southbound funds recorded net purchases of HK$6.477 billion in Hong Kong stocks, including Tencent Holdings Ltd. and AIA, and net sales of several other listed companies.
Source:
- aastocks.com
Oct 7, 2026, 08:12 UTC
Genscript Biotech Corp. shares fell 12.7% to HK$42.90.
Source:
- aastocks.com
Oct 7, 2026, 01:37 UTC
Hong Kong stocks opened lower, with the Hang Seng Index down 108 points (0.45%), the Hang Seng Tech Index down 13 points (0.33%) and the Hang Seng China Enterprises Index down 33 points (0.42%).
Source:
Oct 6, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.
Source:
Sep 30, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 30, 2026, with the Hang Seng Index up 89 points or 0.4% at 24,613 and the Hang Seng Tech Index up 4 points or 0.1% at 4,253, on turnover of HK$187.158 billion.
Source:
Sep 30, 2026, 04:12 UTC
Hong Kong stock indices closed the morning session mixed, with the Hang Seng Index down 10 points at 24,513 and the Hang Seng Tech Index down 6 points at 4,243, while CSPC Pharmaceutical rose over 5% and GenScript Biotech hit a new high.
Source:
- aastocks.com
- aastocks.com
Sep 25, 2026, 02:03 UTC
GenScript Biotech (01548) shares rose as much as 8.15% to an intraday high of HK$42.98 on September 25, 2026, after the company announced a reduction in its board lot size.
Source:
- aastocks.com
- m.21jingji.com
Sep 21, 2026, 23:13 UTC
GenScript Biotech launched a spin-off plan, part of a new wave of Hong Kong spin-off listings.
Source:
- finance.sina.cn
Sep 21, 2026, 09:33 UTC
GenScript Biotech announced that the board lot size of its Hong Kong-listed shares will change from 2,000 shares to 1,000 shares, effective October 14, 2026.
Source:
- aastocks.com
Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:
- aastocks.com
Sep 21, 2026, 02:12 UTC
Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.
Source:
- aastocks.com
Sep 17, 2026, 13:36 UTC
Bestzyme Bio, a subsidiary of GenScript Biotech, completed construction of an automated smart production line for sweet proteins in Jinan, China, the world's first commercial line dedicated to sweet protein production.
Source:
- finance.sina.cn
Sep 17, 2026, 02:03 UTC
GenScript Biotech announced a collaboration with Eli Lilly's AI/machine-learning drug discovery platform Lilly TuneLab, under which GenScript will provide wet-lab services to Lilly TuneLab participating companies.
Source:
Aug 20, 2026, 01:46 UTC
On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.
Source:
- aastocks.com
- aastocks.com

01548.HK

Genscript Biotech Corp. rose 1.166% to HK$34.70.

Hong Kong stocks rose more than 300 points in early trading to 24,392.3, while the Hang Seng Tech Index gained as much as 2.24% to 4,152, with Alibaba and biotechnology shares among the gainers.

Southbound funds recorded net sales of HK$135 million in Hong Kong stocks, with net purchases of Alibaba, Akeso, Inc., Meituan and Tencent and net sales of SMIC, Yangtze Optical Fibre and Cable, Xiaomi Corp., Kingboard Laminates Holdings Ltd. and GenScript.

Legend Biotech Corp announced that CARVYKTI had net trade sales of approximately $710 million for the quarter ended September 30, 2026, based on information provided by JOHNSON & JOHNSON and not independently verified by Legend Biotech Corp or GenScript.

Hong Kong-listed shares showed mixed moves, with China Hongqiao falling 5.3% and several stocks including CK Infrastructure, Agricultural Bank of China, Bank of Communications, China Construction Bank and Bank of China reaching record highs.

Hong Kong-listed shares of Man Wah Holdings Ltd. fell 13.8% to HK$2.37, Genscript Biotech Corp. fell 12.4% to HK$36.90, China Youran Dairy Group Ltd. fell 11.1% to HK$3.43, Mabpharm Ltd. fell 10.8% to HK$19.54, and Brainaurora Medical Technology Ltd. fell 10.1% to HK$0.76.

AIA Group Ltd. recorded net purchases of HK$291 million in Hong Kong-listed shares, including HK$1.066 billion of AIA, and net sales of several other securities.

Genscript Biotech Corp. and NVIDIA CORP jointly launched a pitch competition for life-sciences startups to accelerate biotechnology innovation.

Southbound funds recorded net purchases of HK$6.477 billion in Hong Kong stocks, including Tencent Holdings Ltd. and AIA, and net sales of several other listed companies.

Genscript Biotech Corp. shares fell 12.7% to HK$42.90.

Hong Kong stocks opened lower, with the Hang Seng Index down 108 points (0.45%), the Hang Seng Tech Index down 13 points (0.33%) and the Hang Seng China Enterprises Index down 33 points (0.42%).

Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.

Hong Kong stocks closed higher on September 30, 2026, with the Hang Seng Index up 89 points or 0.4% at 24,613 and the Hang Seng Tech Index up 4 points or 0.1% at 4,253, on turnover of HK$187.158 billion.

Hong Kong stock indices closed the morning session mixed, with the Hang Seng Index down 10 points at 24,513 and the Hang Seng Tech Index down 6 points at 4,243, while CSPC Pharmaceutical rose over 5% and GenScript Biotech hit a new high.

GenScript Biotech (01548) shares rose as much as 8.15% to an intraday high of HK$42.98 on September 25, 2026, after the company announced a reduction in its board lot size.

GenScript Biotech launched a spin-off plan, part of a new wave of Hong Kong spin-off listings.

GenScript Biotech announced that the board lot size of its Hong Kong-listed shares will change from 2,000 shares to 1,000 shares, effective October 14, 2026.

Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

Bestzyme Bio, a subsidiary of GenScript Biotech, completed construction of an automated smart production line for sweet proteins in Jinan, China, the world's first commercial line dedicated to sweet protein production.

GenScript Biotech announced a collaboration with Eli Lilly's AI/machine-learning drug discovery platform Lilly TuneLab, under which GenScript will provide wet-lab services to Lilly TuneLab participating companies.

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.